Author

Jean-Michel Paillarse

Observed names: J M Paillarse, Jean‐Michel Paillarse

Institution: Enterome (France)

Observed institution: Enterome (France)

ORCID: 0000-0002-7113-8491

Observed ORCID: 0000-0002-7113-8491

OpenAlex ID: A5020311495

Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease

2023 · Florian Plaza-Onate, Célia Chamignon, et al. · International Journal of Molecular Sciences · 97

Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD)

2021 · Sebastian D. Burz, Magali Monnoye, et al. · Microorganisms · 76

Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease

2022 · Walter Reinisch, Xavier Hébuterne, et al. · Journal of Gastroenterology and Hepatology · 32

P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD)

2020 · W Reinisch, X Hébuterne, et al. · Journal of Crohn s and Colitis · 13

EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.

2022 · Eric Baudin, Camilo Jimenez, et al. · Journal of Clinical Oncology · 12

Ctim-25. Eo2401 Peptide Immunotherapy + Nivolumab +/- Bevacizumab in First Recurrent Glioblastoma: the Phase 1/2 Eogbm1-18/rosalie Study (nct04116658)

2023 · David Reardon, Ahmed Idbaih, et al. · Neuro-Oncology · 4

Sa1767 - Eb8018, a Novel Fimh Blocker is well Tolerated in a Randomized, Double-Blind, Placebo -Controlled Phase I Study in Healthy Volunteers

2018 · Jaikrishna Patel, Jean-Michel Paillarse, et al. · Gastroenterology · 4

EB8018, a First-In-Class Fimh Blocker, Reduces Proinflammatory Cytokines TNFÎʻ, Il6 and Il8 in Surgical Explants and May Represent a Potential New Therapeutic Approach for the Treatment of Crohn's Disease

2017 · Arnaud Laveissière, Rachel Morra, et al. · Gastroenterology · 2

Tu1900 A PHARMACOKINETIC (PK) AND SAFETY STUDY OF A FIMH BLOCKER, SIBOFIMLOC (TAK-018/EB8018), IN PATIENTS WITH CROHN'S DISEASE (CD)

2020 · Walter Reinisch, Xavier Hebuterne, et al. · Gastroenterology · 1

630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

2023 · Lucie Aubergeon, Eric Baudin, et al. · Journal for ImmunoTherapy of Cancer

638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

2023 · Ana Maia, Hélène Toussaint, et al. · Journal for ImmunoTherapy of Cancer

Tu1854 – Association Between Qpcr Assays Targeting Fims/Fimh and Aggregation to Eb8018 : Results of the Mobidic Study (Molecular Biomarkers and Adherent and Invasive Escherichia COLI (AIEC) Detection Study in Crohn's Disease Patients)

2019 · Jean-Michel Paillarse, Christophe Bonny, et al. · Gastroenterology

Works count: 12

Citation count: 241

H-index: 5

I10-index: 5